Filing Flows › Comparisons › MGX vs TCRX
Metagenomi Therapeutics vs TScan Therapeutics: MGX and TCRX compared
Metagenomi Therapeutics is the larger company: $1.2M of revenue in its latest quarter (Q1 2026) against $1.1M for TScan Therapeutics (Q2 2026). TScan Therapeutics is growing faster (-66% against -70% a year earlier).
Where the money goes: MGX and TCRX
Metagenomi Therapeutics (MGX) · Q1 2026
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
TScan Therapeutics (TCRX) · Q2 2026
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
| Metagenomi Therapeutics (MGX) | TScan Therapeutics (TCRX) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $1.2M | $1.1M |
| Revenue growth, Y/Y | -70% | -66% |
| Operating margin | n/m | n/m |
| Net earnings | −$23.1M | −$30.4M |
| Operating cash flow | −$21.2M | −$27.5M |
Questions
Which is bigger, Metagenomi Therapeutics or TScan Therapeutics?
Metagenomi Therapeutics is the larger company: $1.2M of revenue in its latest quarter (Q1 2026) against $1.1M for TScan Therapeutics (Q2 2026).
Is Metagenomi Therapeutics or TScan Therapeutics growing faster?
TScan Therapeutics is growing faster (-66% against -70% a year earlier).
More: Metagenomi Therapeutics earnings · how Metagenomi Therapeutics makes money · TScan Therapeutics earnings · how TScan Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 11, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.